United States - English - NLM (National Library of Medicine)

nelco laboratories, inc. - house dust (unii: eyo007vx98) (house dust - unii:eyo007vx98) - house dust 10000 [pnu] in 1 ml - allergenic extracts are indicated for use in diagnostic testing and as part of a treatment regime for allergic disease, as established by allergy history and skin test reactivity. allergenic extracts are indicated for the treatment of allergen specific allergic disease for use as hyposensitization or immunotherapy when avoidance of specific allergens can not be attained. the use of allergenic extracts for therapeutic purpose has been established by well-controlled clinical studies. allergenic extracts may be used as adjunctive therapy along with pharmacotherapy which includes antihistamines, corticosteroids, and cromoglycate, and avoidance measures. allergenic extracts for therapeutic use should be given using only the allergen selection to which the patient is allergic, has a history of exposure and are likely to be exposed to again. allergenic extracts should not be used if the patient has asthma, cardiovascular disease, emphysema, diabetes, bleeding diathesis or pregnancy, unless a specific diagnosis of t

United States - English - NLM (National Library of Medicine)

alk-abello, inc. - house dust (unii: eyo007vx98) (house dust - unii:eyo007vx98) - house dust 10000 [pnu] in 1 ml - these products are for diagnostic use only. diagnostic allergenic extracts are indicated for use in skin testing to establish the clinical relevance of specific allergens to which the patient has been exposed. by measuring skin test response, the physician may assess the degree of sensitivity that patients have to the allergens. for extracts standardized in au and bau, see individual directions for use. allergenic extracts for diagnostic use only of coffee, mosquito, cottonseed, and flaxseed have not been shown by adequate data to be safe and effective for therapeutic use. patients on beta blockers can be non-responsive to beta agonists that may be required to reverse a systemic reaction (also, see boxed warning statement and adverse reactions ). the physician should carefully weigh the benefit derived from skin testing vs. the risk to the patient should a systemic reaction arise. patients with unstable asthma or steroid dependent asthmatics and patients with underlying cardiovascular disease are at greater

United States - English - NLM (National Library of Medicine)

antigen laboratories, inc. - house dust (unii: eyo007vx98) (house dust - unii:eyo007vx98) - house dust 0.1 g in 1 ml - allergenic extract is used for diagnostic testing and for the treatment (immunotherapy) of patients whose histories indicate that upon natural exposure to the allergen, they experience allergic symptoms. confirmation is determined by skin testing. diagnostic use of allergenic extracts usually begins with direct skin testing. this product is not intended for treatment of patients who do not manifest immediate hypersensitivity reactions to the allergenic extract following skin testing. do not administer in the presence of diseases characterized by bleeding diathesis. individuals with autoimmune disease may be at risk of exacerbating symptoms of the underlying disease, possibly due to routine immunization. patients who have experienced a recent myocardial infarction may not be tolerant of immunotherapy. children with nephrotic syndrome probably should not receive injections due to immunization causing exacerbation of nephrotic disease.

Australia - English - Department of Health (Therapeutic Goods Administration)

seqirus pty ltd - european house dust mite extract, quantity: 6 sq-hdm; american house dust mite extract, quantity: 6 sq-hdm - tablet - excipient ingredients: gelatin; sodium hydroxide; purified water; mannitol - allergic rhinitis acarizax is indicated for the treatment of house dust mite (hdm) allergic rhinitis not well controlled despite use of symptom relieving medication in adults and adolescents (? 12 years). allergic asthma acarizax is indicated for the treatment of hdm allergic asthma not well controlled by inhaled corticosteroids and associated with hdm allergic rhinitis in adults. patients? asthma status should be carefully evaluated before the initiation of treatment.

Australia - English - Department of Health (Therapeutic Goods Administration)

stallergenes australia pty ltd - american house dust mite extract, quantity: 5 ir/ml; european house dust mite extract, quantity: 5 ir/ml - injection, suspension - excipient ingredients: sodium chloride; phenol; water for injections; aluminium hydroxide hydrate; mannitol - treatment of patients with type 1 allergy (gell and coombs classification), particularly presenting as seasonal or perennial rhinitis, conjunctivitis, rhinoconjunctivitis, with or without associated asthma.

Australia - English - Department of Health (Therapeutic Goods Administration)

stallergenes australia pty ltd - european house dust mite extract, quantity: 5 ir/ml; american house dust mite extract, quantity: 5 ir/ml - injection, suspension - excipient ingredients: aluminium hydroxide hydrate; phenol; sodium chloride; water for injections; mannitol - treatment of patients with type 1 allergy (gell and coombs classification), particularly presenting as seasonal or perennial rhinitis, conjunctivitis, rhinoconjunctivitis, with or without associated asthma.

Australia - English - Department of Health (Therapeutic Goods Administration)

stallergenes australia pty ltd - european house dust mite, quantity: 150 ir; american house dust mite, quantity: 150 ir - tablet - excipient ingredients: magnesium stearate; croscarmellose sodium; lactose monohydrate; microcrystalline cellulose; colloidal anhydrous silica; mannitol - treatment of house dust mite allergic rhinitis with or without conjunctivitis in adults, adolescents and children 5 years and over diagnosed with house dust mite allergy.

Australia - English - Department of Health (Therapeutic Goods Administration)

stallergenes australia pty ltd - european house dust mite, quantity: 150 ir; american house dust mite, quantity: 150 ir - tablet - excipient ingredients: microcrystalline cellulose; croscarmellose sodium; colloidal anhydrous silica; lactose monohydrate; magnesium stearate; mannitol - treatment of house dust mite allergic rhinitis with or without conjunctivitis in adults, adolescents and children 5 years and over diagnosed with house dust mite allergy.

New Zealand - English - Medsafe (Medicines Safety Authority)

stallergenes greer new zealand ltd - dermatophagoides farinae allergen extract 50 ir ((american house dust mite)); dermatophagoides pteronyssinus allergen extract 50 ir ((european house dust mite)); dermatophagoides farinae allergen extract 150 ir ((american house dust mite)); dermatophagoides pteronyssinus allergen extract 150 ir ((dermatophagoides pteronyssinus)) - sublingual tablet - 100ir & 300ir - active: dermatophagoides farinae allergen extract 50 ir ((american house dust mite)) dermatophagoides pteronyssinus allergen extract 50 ir ((european house dust mite)) excipient: colloidal silicon dioxide croscarmellose sodium lactose monohydrate magnesium stearate microcrystalline cellulose active: dermatophagoides farinae allergen extract 150 ir ((american house dust mite)) dermatophagoides pteronyssinus allergen extract 150 ir ((dermatophagoides pteronyssinus)) excipient: colloidal silicon dioxide croscarmellose sodium lactose monohydrate magnesium stearate microcrystalline cellulose - actair is indicated for the treatment of house dust mite allergic rhinitis with or without conjunctivitis in adults, adolescents and children 5 years and over diagnosed with house dust mite allergy.

New Zealand - English - Medsafe (Medicines Safety Authority)

stallergenes greer new zealand ltd - dermatophagoides farinae allergen extract 150 ir ((american house dust mite)); dermatophagoides pteronyssinus allergen extract 150 ir ((european house dust mite)) - sublingual tablet - 300 ir - active: dermatophagoides farinae allergen extract 150 ir ((american house dust mite)) dermatophagoides pteronyssinus allergen extract 150 ir ((european house dust mite)) excipient: colloidal silicon dioxide croscarmellose sodium lactose monohydrate magnesium stearate microcrystalline cellulose - actair is indicated for the treatment of house dust mite allergic rhinitis with or without conjunctivitis in adults, adolescents and children 5 years and over diagnosed with house dust mite allergy.